In this update on InMed Pharmaceuticals, CEO Eric A. Adams talks about the company’s Alzheimer’s disease program.
Mr. Adams talks about the role of inflammation in Alzheimer’s disease and how inflammation is not only the response to neuronal damage but it can also perpetuate the cycle of Alzheimer’s disease, creating a vicious cycle that exacerbates disease progression.
In this video, Mr. Adams also presents data on InMed’s Alzheimer’s disease drug candidate INM-901, which shows the potential to target multiple pharmacological pathways involved in Alzheimer’s, including inflammation. Preclinical studies have shown how INM-901 has significantly reduced inflammatory markers known to be involved in Alzheimer’s progression.
This conference presentation was originally presented on December 11, 2025 at the Life Sciences Virtual Investor Forum.
